ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025
Assessment of Expressor Lymphoma Prevalence in High-Grade Large B-cell Lymphomas: An Observational Analysis From a Tertiary Care Centre.
Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Double or Triple Hit Lymphomas (DHL/THL) represent a subset of aggressive B-cell lymphomas with markedly poorer outcomes and survival rates compared to Diffuse Large B-cell Lymphomas, NOS (DLBCL, NOS). Identifying the Hit status in High-grade large B-cell lymphoma (HGBL)/ Diffuse Large B-cell Lymphomas (used synonymously henceforth) can aid in identifying cases with aggressive clinical course that may benefit from more intensive chemotherapy. Utilizing immunohistochemistry (IHC) to detect Expressor Lymphomas (EL) provides a simpler and cost-effective means to screen DLBCL cases for further molecular studies aimed at identifying potential Hit status. Our investigation aimed to assess the occurrence of Expressor Lymphoma cases in the Indian population and compare clinical (age, gender, site of tumor and B-symptoms) and pathological parameters {Ki67 proliferation index and Germinal Centre/Non-Germinal Centre (GC/Non-GC) phenotype} between Expressor and Non-Expressor Lymphomas (NEL). The present study included 131 patients diagnosed with HGBL. Men comprised 62.6% of patients, with 58% aged 60 years or younger. Clinical data on the occurrence of B-symptoms was accessible for 99 patients, with only 35 of them displaying such symptoms. Serum LDH levels were measured in 34 of the 131 total cases, and 30 of these showed elevated levels. Nodal disease was present in 26% of cases, while the remaining had extranodal involvement. The GC phenotype was observed in 58.8% of cases. Out of 131 cases, 22.2% were EL, while 77.8% were NEL. ELs exhibited a higher mean Ki67 value (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.